Sarepta Therapeutics Management
Management criteria checks 2/4
Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 8.67 years. total yearly compensation is $1.98M, comprised of 42.8% salary and 57.2% bonuses, including company stock and options. directly owns 0.89% of the company’s shares, worth $19.26M. The average tenure of the management team and the board of directors is 0.6 years and 9.7 years respectively.
Key information
Doug Ingram
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 42.81% |
| CEO tenure | 8.7yrs |
| CEO ownership | 0.9% |
| Management average tenure | less than a year |
| Board average tenure | 9.7yrs |
Recent management updates
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
May 29
Recent updates
Sarepta Therapeutics: Is Elevidys A Bust?
Jan 16There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues Despite A 35% Share Price Rise
Dec 04Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 32% But Its Business Still Trails The Industry
Oct 18We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right
May 29The Consensus EPS Estimates For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Fell A Lot
May 08Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 20Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Mar 18Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Low P/S No Reason For Excitement
Mar 05Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Mar 04These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well
Jan 22Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Jan 16Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19
ELEVIDYS Launch And Calculated Expansions Set To Skyrocket Revenue Growth
Broad approval of ELEVIDYS for Duchenne muscular dystrophy signifies potential revenue growth due to strong early launch performance.Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$272m |
| Jun 30 2025 | n/a | n/a | -US$58m |
| Mar 31 2025 | n/a | n/a | -US$248m |
| Dec 31 2024 | US$2m | US$847k | US$235m |
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
Compensation vs Market: Doug's total compensation ($USD1.98M) is below average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
CEO
Doug Ingram (62 yo)
Mr. Douglas S. Ingram, J.D., Esq., also known as Doug, serves as Independent Director of Arrowhead Pharmaceuticals, Inc. since February 06, 2025. He has been Chief Executive Officer Sarepta Therapeutics, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8.7yrs | US$1.98m | 0.89% $ 19.3m | |
| President & COO | less than a year | US$2.75m | 0.18% $ 4.0m | |
| President of Research & Development and Technical Operations | less than a year | US$2.74m | 0.21% $ 4.6m | |
| Executive VP & CFO | less than a year | no data | 0.13% $ 2.8m | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Director of Finance | no data | no data | no data | |
| Executive VP | 1.3yrs | no data | no data | |
| Executive VP & Chief People Officer | 4.3yrs | no data | no data | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 6.4yrs | no data | no data | |
| Executive VP & Chief Commercial Officer | less than a year | no data | no data | |
| Executive VP & Chief Medical Officer | less than a year | no data | no data | |
| Controller & VP | 8.9yrs | US$911.89k | no data |
Experienced Management: SRPT's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 8.7yrs | US$1.98m | 0.89% $ 19.3m | |
| Independent Chairwoman | 16.9yrs | US$616.95k | 0.20% $ 4.2m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 15.7yrs | US$572.02k | 0.022% $ 473.3k | |
| Independent Director | 10.7yrs | US$593.20k | 3.07% $ 66.6m | |
| Member of Strategic & Scientific Advisory Board | 10.5yrs | no data | no data | |
| Independent Director | 1.4yrs | US$730.98k | no data | |
| Member of Strategic & Scientific Advisory Board | 10.5yrs | no data | no data | |
| Independent Non-Employee Director | 10.7yrs | US$564.64k | 0.028% $ 604.0k | |
| Member of Strategic & Scientific Advisory Board | 8.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.2yrs | no data | no data | |
| Member of Strategic & Scientific Advisory Board | 8.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data |
Experienced Board: SRPT's board of directors are considered experienced (9.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 12:04 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sarepta Therapeutics, Inc. is covered by 54 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Huidong Wang | Barclays |
| Yun Zhong | Berenberg |